• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国356例三阴性乳腺癌患者的临床特征及预后分析

Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.

作者信息

Zhang Li, Hao Chunfang, Dong Guolei, Tong Zhongsheng

机构信息

Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Cancer Research Key Laboratory of Education Ministry, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin, China.

出版信息

Breast Care (Basel). 2012 Feb;7(1):13-17. doi: 10.1159/000336539. Epub 2012 Feb 13.

DOI:10.1159/000336539
PMID:22553467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335351/
Abstract

BACKGROUND

The purpose of this study was to investigate the clinicopathological features and analyze the prognostic factors of triple-negative breast cancer (TNBC). PATIENTS AND METHODS: The clinical data of 1,788 breast cancer patients was collected and analyzed. The Kaplan-Meier method was used to estimate survival. Multivariate analysis of the prognostic factors for survival was performed using the Cox regression model. RESULTS: Patients with TNBC exhibited characteristics significantly differing from those with non-TNBC. There was a higher proportion of patients with age < 35 years, stage III disease, tumor size > 5 cm, lymph node positivity, and histological grade 3. The 5-year disease-free survival (DFS) rates of TNBC and non-TNBC patients were 75.7 and 79.6%, respectively (p < 0.05). 5-year overall survival (OS) was 86.6 and 93.5%, respectively (p < 0.05). In multivariate Cox regression analysis, the independent prognostic factors for shorter DFS were age < 35 years (hazard ratio (HR) 2.105), positive lymph nodes (HR 7.039), histological grade 3 (HR 1.841), and for shorter OS positive lymph nodes (HR 4.626). CONCLUSION: The proportion of TNBC in breast cancer in China is higher than in other areas. TNBC is correlated with younger age, larger tumor size, positive lymph nodes, higher clinical stage and histological grade, and lower DFS and OS, which is consistent with previous reports.

摘要

背景

本研究旨在探讨三阴性乳腺癌(TNBC)的临床病理特征并分析其预后因素。

患者与方法

收集并分析1788例乳腺癌患者的临床资料。采用Kaplan-Meier法估计生存率。使用Cox回归模型对生存预后因素进行多变量分析。

结果

TNBC患者表现出与非TNBC患者显著不同的特征。年龄<35岁、Ⅲ期疾病、肿瘤大小>5cm、淋巴结阳性和组织学3级的患者比例更高。TNBC和非TNBC患者的5年无病生存率(DFS)分别为75.7%和79.6%(p<0.05)。5年总生存率(OS)分别为86.6%和93.5%(p<0.05)。在多变量Cox回归分析中,DFS较短的独立预后因素为年龄<35岁(风险比(HR)2.105)、淋巴结阳性(HR 7.039)、组织学3级(HR 1.841),OS较短的独立预后因素为淋巴结阳性(HR 4.626)。

结论

中国乳腺癌中TNBC的比例高于其他地区。TNBC与较年轻的年龄、较大的肿瘤大小、淋巴结阳性、较高的临床分期和组织学分级相关,且DFS和OS较低,这与先前的报道一致。

相似文献

1
Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.中国356例三阴性乳腺癌患者的临床特征及预后分析
Breast Care (Basel). 2012 Feb;7(1):13-17. doi: 10.1159/000336539. Epub 2012 Feb 13.
2
Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.氟尿嘧啶、表柔比星和环磷酰胺辅助化疗治疗三阴性乳腺癌患者的预后分析
Oncol Lett. 2016 Mar;11(3):2320-2326. doi: 10.3892/ol.2016.4176. Epub 2016 Feb 2.
3
Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China.2 型糖尿病对中国早期三阴性乳腺癌患者预后的影响。
Onco Targets Ther. 2014 Nov 27;7:2147-54. doi: 10.2147/OTT.S71095. eCollection 2014.
4
Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.接受TAC化疗方案的马来西亚三阴性乳腺癌患者的临床病理特征及预后特征
Int J Breast Cancer. 2020 Apr 1;2020:8424365. doi: 10.1155/2020/8424365. eCollection 2020.
5
The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients.NEDD9和E-钙黏蛋白的表达与三阴性乳腺癌患者的转移及不良预后相关。
Onco Targets Ther. 2016 Sep 19;9:5751-5759. doi: 10.2147/OTT.S113768. eCollection 2016.
6
The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.三阴性乳腺癌患者的治疗结果:土耳其肿瘤学组的经验
J Breast Health. 2014 Oct 1;10(4):209-215. doi: 10.5152/tjbh.2014.1904. eCollection 2014 Oct.
7
Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.三阴性乳腺癌与非三阴性乳腺癌的临床病理特征及预后比较
J Cancer. 2016 Jan 1;7(2):167-73. doi: 10.7150/jca.10944. eCollection 2016.
8
Clinicopathological features of triple-negative breast cancer in Taiwanese women.台湾地区女性三阴性乳腺癌的临床病理特征。
Int J Clin Oncol. 2011 Oct;16(5):500-5. doi: 10.1007/s10147-011-0211-9. Epub 2011 Apr 1.
9
Clinical characteristics and prognostic analysis of triple-negative breast cancer patients.三阴性乳腺癌患者的临床特征及预后分析
Mol Clin Oncol. 2014 Mar;2(2):245-251. doi: 10.3892/mco.2013.230. Epub 2013 Dec 20.
10
Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients.三阴性乳腺癌患者中激肽释放酶相关肽酶 12(KLK12)mRNA 表达的预后价值。
Mol Med. 2020 Feb 7;26(1):19. doi: 10.1186/s10020-020-0145-7.

引用本文的文献

1
Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer.基于泛癌中胚胎和造血干细胞特征识别癌症亚型。
Cell Oncol (Dordr). 2024 Apr;47(2):587-605. doi: 10.1007/s13402-023-00886-7. Epub 2023 Oct 12.
2
The Association between Early-Onset Diagnosis and Clinical Outcomes in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.三阴性乳腺癌的早发诊断与临床结局之间的关联:一项系统评价和荟萃分析
Cancers (Basel). 2023 Mar 23;15(7):1923. doi: 10.3390/cancers15071923.
3
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.中国一线晚期转移性三阴性乳腺癌治疗中顺铂联合吉西他滨与紫杉醇联合吉西他滨的经济学评价:使用马尔可夫模型和分割生存模型。
Adv Ther. 2020 Sep;37(9):3761-3774. doi: 10.1007/s12325-020-01418-7. Epub 2020 Jul 9.
4
A chemical toolbox for the study of bromodomains and epigenetic signaling.溴结构域和表观遗传信号研究的化学工具包。
Nat Commun. 2019 Apr 23;10(1):1915. doi: 10.1038/s41467-019-09672-2.
5
Overexpression of miR-509 Increases Apoptosis and Inhibits Invasion via Suppression of Tumor Necrosis Factor-α in Triple-Negative Breast Cancer Hs578T Cells.miR-509过表达通过抑制三阴性乳腺癌Hs578T细胞中的肿瘤坏死因子-α增加细胞凋亡并抑制侵袭。
Oncol Res. 2016;24(4):233-8. doi: 10.3727/096504016X14648701447977.
6
Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.氟尿嘧啶、表柔比星和环磷酰胺辅助化疗治疗三阴性乳腺癌患者的预后分析
Oncol Lett. 2016 Mar;11(3):2320-2326. doi: 10.3892/ol.2016.4176. Epub 2016 Feb 2.
7
Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.三阴性乳腺癌与非三阴性乳腺癌的临床病理特征及预后比较
J Cancer. 2016 Jan 1;7(2):167-73. doi: 10.7150/jca.10944. eCollection 2016.
8
Carnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer.鼠尾草酸通过活性氧介导的非贝克林1自噬诱导三阴性乳腺癌细胞发生自噬和凋亡。
PLoS One. 2014 Oct 9;9(10):e109630. doi: 10.1371/journal.pone.0109630. eCollection 2014.
9
Clinical characteristics and prognostic analysis of triple-negative breast cancer patients.三阴性乳腺癌患者的临床特征及预后分析
Mol Clin Oncol. 2014 Mar;2(2):245-251. doi: 10.3892/mco.2013.230. Epub 2013 Dec 20.
10
TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis.三阴性乳腺癌细胞系中肿瘤坏死因子-α基因敲除诱导细胞凋亡。
Int J Mol Sci. 2012 Dec 24;14(1):411-20. doi: 10.3390/ijms14010411.

本文引用的文献

1
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.基于雌激素受体(ER)/孕激素受体(PR)和人表皮生长因子受体2(Her2)表达的乳腺癌亚型:临床病理特征与生存情况比较
Clin Med Res. 2009 Jun;7(1-2):4-13. doi: 10.3121/cmr.2009.825.
2
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.淋巴结阴性乳腺癌中三阴性的临床病理特征及预后意义
BMC Cancer. 2008 Oct 23;8:307. doi: 10.1186/1471-2407-8-307.
3
[Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases].三阴性乳腺癌的临床特征与预后:305例报告
Ai Zheng. 2008 Jun;27(6):561-5.
4
The prognostic importance of triple negative breast carcinoma.三阴性乳腺癌的预后重要性。
Breast. 2008 Aug;17(4):341-6. doi: 10.1016/j.breast.2007.11.031. Epub 2008 May 1.
5
The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.人表皮生长因子受体2在雌激素和孕激素受体阴性浸润性乳腺癌女性患者生存中的作用:加利福尼亚癌症登记处,1999 - 2004年
Cancer. 2008 Feb 15;112(4):737-47. doi: 10.1002/cncr.23243.
6
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.新辅助多西他赛和阿霉素化疗治疗Ⅱ/Ⅲ期乳腺癌时临床病理参数的预后影响:三阴性乳腺癌的矛盾特征
BMC Cancer. 2007 Nov 1;7:203. doi: 10.1186/1471-2407-7-203.
7
Triple-negative breast cancer: clinical features and patterns of recurrence.三阴性乳腺癌:临床特征与复发模式
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. doi: 10.1158/1078-0432.CCR-06-3045.
8
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.三阴性悖论:乳腺癌亚型的原发性肿瘤化疗敏感性
Clin Cancer Res. 2007 Apr 15;13(8):2329-34. doi: 10.1158/1078-0432.CCR-06-1109.
9
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.雌激素受体(ER)阴性、孕激素受体(PR)阴性和人表皮生长因子受体2(HER2)阴性浸润性乳腺癌(即所谓的三阴性表型)的描述性分析:一项基于加利福尼亚癌症登记处数据的人群研究
Cancer. 2007 May 1;109(9):1721-8. doi: 10.1002/cncr.22618.
10
Triple-negative breast cancer: therapeutic options.三阴性乳腺癌:治疗选择
Lancet Oncol. 2007 Mar;8(3):235-44. doi: 10.1016/S1470-2045(07)70074-8.